Vaxcyte, Inc. (PCVX)
62.63
+1.17
(+1.90%)
USD |
NASDAQ |
Oct 29, 16:00
62.63
0.00 (0.00%)
After-Hours: 20:00
Vaxcyte Enterprise Value : 7.527B for Oct. 28, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 28, 2026 | 7.527B |
| October 27, 2026 | 7.413B |
| October 26, 2026 | 7.311B |
| October 23, 2026 | 7.378B |
| October 22, 2026 | 7.728B |
| October 21, 2026 | 7.783B |
| October 20, 2026 | 8.218B |
| October 19, 2026 | 7.849B |
| October 16, 2026 | 7.840B |
| October 15, 2026 | 8.079B |
| October 14, 2026 | 8.409B |
| October 13, 2026 | 8.300B |
| October 12, 2026 | 8.858B |
| October 09, 2026 | 8.963B |
| October 08, 2026 | 8.042B |
| October 07, 2026 | 8.323B |
| October 06, 2026 | 8.286B |
| October 05, 2026 | 9.317B |
| October 02, 2026 | 6.806B |
| October 01, 2026 | 6.744B |
| September 30, 2026 | 6.867B |
| September 29, 2026 | 6.837B |
| September 28, 2026 | 7.065B |
| September 25, 2026 | 6.767B |
| September 24, 2026 | 6.867B |
| Date | Value |
|---|---|
| September 23, 2026 | 6.808B |
| September 22, 2026 | 7.174B |
| September 21, 2026 | 7.159B |
| September 18, 2026 | 7.045B |
| September 17, 2026 | 7.369B |
| September 16, 2026 | 7.138B |
| September 15, 2026 | 7.201B |
| September 14, 2026 | 7.249B |
| September 11, 2026 | 7.239B |
| September 10, 2026 | 7.156B |
| September 09, 2026 | 7.245B |
| September 08, 2026 | 7.368B |
| September 04, 2026 | 7.484B |
| September 03, 2026 | 7.485B |
| September 02, 2026 | 7.545B |
| September 01, 2026 | 7.433B |
| August 31, 2026 | 7.423B |
| August 28, 2026 | 7.292B |
| August 27, 2026 | 7.483B |
| August 26, 2026 | 7.474B |
| August 25, 2026 | 7.474B |
| August 24, 2026 | 7.587B |
| August 21, 2026 | 7.695B |
| August 20, 2026 | 7.510B |
| August 19, 2026 | 7.794B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Moderna, Inc. | 81.60B |
| Vir Biotechnology, Inc. | 1.577B |
| Revolution Medicines, Inc. | 37.68B |
| Arrowhead Pharmaceuticals, Inc. | 8.272B |
| Oncolytics Biotech, Inc. | 51.37M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -284.30M |
| Total Expenses (Quarterly) | 284.30M |
| EPS Diluted (Quarterly) | -1.968 |
| Earnings Yield | -12.31% |
| Normalized Earnings Yield | -12.31 |